Replies to post #428 on Aratana Therapeutics Inc (fka PETX)

[biotech_researcher]

INTL, there is no upside, high risk:

Aratana Therapeutics (NASDAQ:PETX): Q4 GAAP EPS of -$0.18.
• Revenue of $4.91M (-53.1% Y/Y) misses by $1.61M.